UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for osteoporosis in the United Kingdom. Explore treatment pathways including bisphosphonates, anabolic agents, and novel therapies.
Osteoporosis affects ~3.5 million people in the UK, causing ~500,000 fragility fractures yearly. It weakens bones, making them break easily from minor falls or even coughing. Hip fractures alone cost the NHS ~£2 billion/year. Women are more affected (postmenopausal bone loss), but men get osteoporosis too. DEXA scans measure bone density and assess fracture risk using the FRAX tool.
First-line: oral bisphosphonates (alendronate, risedronate) - reduce fracture risk by ~50%. If intolerant: IV bisphosphonate (zoledronic acid, annual infusion) or denosumab (Prolia, 6-monthly injection). For high fracture risk: anabolic agents build new bone - teriparatide (daily injection, 2 years), romosozumab (Evenity, monthly injection, 1 year) followed by bisphosphonate to maintain gains. HRT (hormone replacement therapy) is an option for postmenopausal women.
Active UK osteoporosis trials include: novel anabolic agents, longer-acting bisphosphonates, new drug delivery methods, exercise interventions combined with medication, falls prevention programmes, vitamin D/calcium optimisation studies, and fracture liaison service models. The Royal Osteoporosis Society and NHS fracture liaison services support research across the UK.
We'll email you when new UK clinical trials start recruiting. Free, and you can unsubscribe anytime.
Free AI-powered matching - no signup required
